What is Exact Sciences?
Cancer diagnostics company with $3.25B 2025 revenue scale and public-market buying capacity.
- Category
- Cancer diagnostics
- Headquarters
- Madison, WI
- Founded
- 1995
- Employees
- 7,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: EXAS; Public company
What is Exact Sciences?
Exact Sciences is a public cancer diagnostics company headquartered in Madison, WI. Exact Sciences reported total 2025 revenue of $3.25 billion, up 18%, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million.
Exact Sciences operates in cancer diagnostics with a portfolio that includes Cologuard, Oncotype DX, Cancerguard, Riskguard. Exact Sciences reported total 2025 revenue of $3.25 billion, up 18%, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million. The company employs about 7,000+ and trades as Nasdaq: EXAS, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Exact Sciences through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Exact Sciences is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Exact Sciences offer?
Exact Sciences offers products and services across Cologuard, Oncotype DX, Cancerguard, Riskguard and related healthcare workflows.
- Cologuard· Colorectal cancer screening
- Oncotype DX· Precision oncology
- Cancerguard· Multi-cancer early detection
- Riskguard· Hereditary cancer
- Screening services· Patient access
- Precision oncology testing· Clinical diagnostics
How does Exact Sciences make money?
Exact Sciences earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Exact Sciences earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $3.25B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Exact Sciences improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Exact Sciences?
Exact Sciences is led by Kevin Conroy, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Kevin ConroyChairman and Chief Executive OfficerCEO since 2009Leads Cologuard, oncology diagnostics, and multi-cancer screening strategy.
- Aaron BloomerChief Financial OfficerCFO in 2026Oversees finance, profitability, and capital allocation.
- Tom BeerChief Medical OfficerCMO in 2026Guides clinical evidence and medical strategy.
- Sarah CondellaChief Human Resources OfficerSenior executiveLeads people strategy through diagnostics scale-up.
How do you contact Exact Sciences's leadership?
Exact Sciences publishes official Exact Sciences investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Exact Sciences investor-relations contact route; personal executive email format not verified- Kevin ConroyChairman and Chief Executive Officerofficial Exact Sciences investor-relations contact route
How much funding has Exact Sciences raised?
Exact Sciences is a mature public company, not a venture-backed startup. It trades as Nasdaq: EXAS and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Exact Sciences's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: EXAS, $3.25B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Exact Sciences has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Exact Sciences get here?
Exact Sciences grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1995Exact Sciences incorporatedThe company begins developing molecular diagnostics.
- 2001IPOExact Sciences becomes public.
- 2014Cologuard approvedThe FDA approves Cologuard for colorectal cancer screening.
- 2019Genomic Health acquisitionExact expands precision oncology with Oncotype DX.
- 2025$3.25B revenueExact reports record 2025 revenue of $3.25 billion.
- 2026Growth continuesExact enters 2026 with Screening and Precision Oncology scale.
Who are Exact Sciences's competitors?
Exact Sciences competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- Guardant HealthCompetes in blood-based cancer testing and precision oncology.
- NateraCompetes in molecular diagnostics, oncology monitoring, and genetic testing.
- GRAILCompetes in multi-cancer early detection.
- Foundation MedicineCompetes in comprehensive genomic profiling and oncology decision support.
- Myriad GeneticsCompetes in hereditary cancer and molecular diagnostics.
- Quest DiagnosticsCompetes in advanced diagnostics distribution and laboratory services.
Exact Sciences — frequently asked questions
